Analyst Price Target is $7.88
▲ +35.54% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catalyst Pharmaceuticals in the last 3 months. The average price target is $7.88, with a high forecast of $11.00 and a low forecast of $5.50. The average price target represents a 35.54% upside from the last price of $5.81.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Catalyst Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.